Mesotrypsin has been identified as a facilitator of cancer progression thereby suggesting mesotrypsin could represent a druggable target, but currently no small molecule inhibitors demonstrate enough discrimination between trypsin family members. This evidence concerns the gene PRSS3 and cancer.